Zoetis Inc. (ZTS): Among The Most Oversold S&P 500 Stocks So Far in 2026

The steadfast noted increasing contention and a displacement successful request successful the carnal wellness marketplace arsenic the crushed down the adjustment. Argus besides mentioned the hazard of cannibalization with the company’s starring pipeline products apt to adversely interaction the income of its existent portfolio.

The update follows Stifel’s accommodation connected May 22 erstwhile it trimmed the terms people connected Zoetis Inc. (NYSE:ZTS) to $95 from $105 and reiterated a Hold rating. The steadfast believes that portion the company’s revised guidance for 2026 hints astatine an improvement, competitory pressures “appear poised to intensify” successful the short-term.

As of the adjacent of concern connected May 29, Wall Street has a Moderate Buy standing connected the banal with an mean stock terms upside imaginable of 53%.

The institution missed Wall Street’s expectations for some gross and nett successful Q1 and chopped its full-year guidance, arsenic a cautious user situation continues to interaction request for veterinary visits and premium favored treatments.

Zoetis Inc. (NYSE:ZTS) is simply a planetary carnal wellness institution focused connected processing and commercializing vaccines and medications.

While we admit the imaginable of ZTS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Performing Defense Stocks So Far successful 2026 and 10 Stocks That Will Make You Rich Over the Next Decade.

Disclosure: None. Follow Insider Monkey connected Google News.